-
公开(公告)号：US12234258B2
公开(公告)日：2025-02-25
申请号：US17736057
申请日：2022-05-03
Applicant: GOLDPORP PHARMA LIMITED
Inventor： Chiming Che , Laiking Sy , Chunnam Lok
Abstract: Provided herein are timosaponin compounds of Formula I, II, III, I′, II′ and III′, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are uses of said timosaponin compounds for preparing medicament for the treatment of diseases associated with beta-amyloid in hosts or subjects in need thereof.
-
公开(公告)号：US12233101B2
公开(公告)日：2025-02-25
申请号：US17682190
申请日：2022-02-28
Applicant: NATUREX Inc.
IPC: A61K36/45 , A61K9/00 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/09 , A61K31/192 , A61K31/216 , A61K31/34 , A61K31/341 , A61K31/352 , A61K31/353 , A61K31/7048
Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.
-
公开(公告)号：US12227767B2
公开(公告)日：2025-02-18
申请号：US17166004
申请日：2021-02-03
Inventor： Pierre Roux , Nikola Arsic , Gilles Gadea , Philippe Fort , Fanny Tomas , Véronique Gire
IPC: C12Q1/68 , A61K31/704 , A61K31/7048 , C07K14/47 , C12N5/095 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms expression; and also to screening methods for anti-cancer stem cells agents.
-
公开(公告)号：US20250049831A1
公开(公告)日：2025-02-13
申请号：US18715284
申请日：2022-11-29
Applicant: Xin GE
Inventor： Xin GE , Shuo WANG , Mingming LU , Rongxin LIN , Zifeng YANG , Nanshan ZHONG , Dayun SUI , Wei YANG , Qinhai MA , Kesi LU
IPC: A61K31/7048 , A61K31/341 , A61P31/14 , C07H15/26
Abstract: The present invention provides an application of a bisepoxylignan compound or a bisepoxylignan composition in prevention and treatment of infections with influenza viruses, parainfluenza viruses, COVID-19 viruses and COVID-19 virus variants, an application thereof in prevention and treatment of pulmonary hemorrhage caused by the COVID-19 viruses and the COVID-19 virus variants (e.g., Delta), an application thereof in anti-inflammatory effects on pneumonia caused by influenza viruses, parainfluenza viruses, COVID-19 viruses and COVID-19 virus variants. In addition, the present invention further provides a chemical synthesis method of a bisepoxylignan compound lianqiaoxinside.
-
公开(公告)号：US12220419B2
公开(公告)日：2025-02-11
申请号：US17269004
申请日：2019-08-21
Applicant: Newave Pharmaceutical Inc.
Inventor： Yi Chen
IPC: A61K31/553 , A61K31/282 , A61K31/4184 , A61K31/4745 , A61K31/4985 , A61K31/519 , A61K31/52 , A61K31/635 , A61K31/7048 , A61K33/243 , A61K35/17 , A61K38/07 , A61K39/395 , A61K47/68 , A61P35/02 , C07D471/14 , C07D491/147 , C07D498/14 , C07D498/22 , C07D513/14 , C07D515/14 , C07D519/00
Abstract: The disclosure includes compounds of Formula (A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
-
公开(公告)号：US20250042961A1
公开(公告)日：2025-02-06
申请号：US18716399
申请日：2022-12-05
Applicant: MERCK SHARP & DOHME LLC , MSD International GMBH , Agency for Science, Technology and Research
Inventor： Hubert Josien , Arun Chandramohan , Charles William Johannes , Christopher J. Brown , Srinivasaraghavan Kannan , Anthony William Partridge , Chandra Shekhar Verma , Lin Yan , Tsz Ying Yuen
IPC: C07K14/47 , A61K31/203 , A61K31/4745 , A61K31/475 , A61K31/495 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K33/243 , A61K38/00 , A61K38/12 , A61K38/14 , A61K39/395
Abstract: Disclosed are p53 peptidomimetic macrocycles, each p53 peptidomimetic macrocycle comprising an i, i+4 olefin staple and a polypeptide tail covalently linked to the p53 peptidomimetic macrocycle; an i, i+7 olefin staple and a polypeptide tail covalently linked to the p53 peptidomimetic macrocycle; or, an i, i+7 di-alkyne staple and optionally a polypeptide tail covalently linked to the p53 peptidomimetic macrocycle; wherein the p53 peptidomimetic macrocycle comprises all D-configuration amino acids and the polypeptide tail comprises three to nine amino acids, each amino acid of the polypeptide tail independently having a D-configuration or an L-configuration. The p53 peptidomimetic macrocycles are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX, thereby antagonizing MDM2 and MDMX binding to p53. These p53 peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.
-
公开(公告)号：US20250041313A1
公开(公告)日：2025-02-06
申请号：US18784488
申请日：2024-07-25
Applicant: CITY OF HOPE
Inventor： Ravi Salgia , Tamara Mirzapoiazova , Steven Rosen
IPC: A61K31/555 , A61K31/277 , A61K31/42 , A61K31/4995 , A61K31/7048 , A61K39/00 , A61P35/00
Abstract: Described herein, inter alia, are combination therapies for the treatment of lung cancer.
-
8.发明授权
公开(公告)号：US12216119B2
公开(公告)日：2025-02-04
申请号：US16642863
申请日：2018-08-28
Applicant: THE CGP LAB LIMITED
Inventor： Jian Guan
IPC: G01N33/569 , A61K31/352 , A61K31/7048 , A61K36/185
Abstract: Described herein are improvements relating to IGF-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing organic or plant based material such as concentrated extract of blackcurrant anthocyanins (BCA) for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 ratio along with a means to adjust cGP and cGP/IGF-1 ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data.
-
公开(公告)号：US12214146B2
公开(公告)日：2025-02-04
申请号：US17118143
申请日：2020-12-10
Applicant: Biocoat, Incorporated
Inventor： William James Work , Raymond Joseph Gould , Dhruv Patel , Robert W Hergenrother
IPC: A61M25/10 , A61K31/145 , A61K31/155 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/437 , A61K31/4409 , A61K31/473 , A61K31/502 , A61K31/505 , A61K31/506 , A61K31/52 , A61K31/53 , A61K31/5377 , A61K31/655 , A61K31/7008 , A61K31/7048 , A61K31/7076 , A61K31/708 , A61L29/08 , A61L29/16 , B05D5/00 , B05D7/00
Abstract: The present invention is an implantable medical device comprising (i) a base coat layer having an inner and outer surface, the inner surface of the base coat layer contacting the implantable medical device; (ii) a top-coat layer of a hydrophilic polymer chemically crosslinked and covalently bonded to the outer surface of the base coat layer, the hydrophilic polymer comprising an anionic polyelectrolyte; and (iii) an amount of a hydrophilic cationic drug agent added to the top-coat layer sufficient to provide an effective dosage of the drug agent for delivery to a patient, whereby the hydrophilic cationic drug agent is initially adsorbed into the anionic polyelectrolyte of the top-coat layer and the hydrophilic cationic drug agent having a release rate after the medical device is implanted within a patient's body.
-
公开(公告)号：US12214004B2
公开(公告)日：2025-02-04
申请号：US17096031
申请日：2020-11-12
Applicant: Genome And Company
Inventor： Hansoo Park , Shinyoung Park , Eun Ju Lee , Jae-Sung Yeon , Hye Hee Jeon , Wonduck Kim , Joo-Yeon Chung , Areum Jeong , Youn Kyung Houh , Jinyoung Sohn , Yun Yeon Kim , Sang Gyun Kim , Suro Lee
IPC: A61K35/745 , A61K31/282 , A61K31/337 , A61K31/475 , A61K31/513 , A61K31/519 , A61K31/675 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K33/243 , A61K35/744 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/28 , C12N1/20 , A61K39/00
Abstract: The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect.
